BLU(Delisted)
BELLUS Health·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BLU
Bellus Health Inc.
A clinical-stage biopharmaceutical company that developing novel therapeutics for refractory chronic cough and other cough hypersensitivity indications
275 Armand-Frappier Blvd., Laval, Quebec H7V 4A7, Canada
--
BELLUS Health Inc., was incorporated on April 12, 2012 under the Canadian Business Companies Act. The company is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of chronic cough and other hypersensitivity diseases.
Company Financials
EPS
BLU has released its 2023 Q1 earnings. EPS was reported at -0.2, versus the expected -0.18, missing expectations. The chart below visualizes how BLU has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BLU has released its 2023 Q1 earnings report, with revenue of 3.00K, reflecting a YoY change of -25.00%, and net profit of -25.06M, showing a YoY change of -74.61%. The Sankey diagram below clearly presents BLU's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
